Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients
暂无分享,去创建一个
David R. Jones | S. Sihag | V. Rusch | Laura H. Tang | M. Bains | M. Gonen | D. Coit | Y. Janjigian | Sam S. Yoon | M. Nakauchi | V. Strong | D. Molena | R. Carr | E. Vos | A. Barbetta | A. Russo | Sam S. Yoon
[1] David R. Jones,et al. Incidence and Risk Factors for Isolated Esophageal Cancer Recurrence to the Brain. , 2020, The Annals of thoracic surgery.
[2] Quan P. Ly,et al. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] M. Egger,et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.
[4] S. Barni,et al. Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis , 2019 .
[5] David R. Jones,et al. Patterns and risk of recurrence in patients with esophageal cancer with a pathologic complete response after chemoradiotherapy followed by surgery , 2019, The Journal of thoracic and cardiovascular surgery.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] S. Friesland,et al. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial. , 2018, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[8] Fenghua Wang,et al. Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study , 2018, Cancer medicine.
[9] Kazuhiro Yoshida,et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial , 2018, The Lancet.
[10] B. O'neill,et al. ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS) , 2017, BMC Cancer.
[11] V. Gebski,et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG , 2017, Annals of Surgical Oncology.
[12] D. Fleischer,et al. Incidence of brain metastasis from esophageal cancer. , 2017, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.
[13] C. Compton,et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.
[14] S. Hochwald,et al. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. , 2016, Journal of the American College of Surgeons.
[15] C. Schmoor,et al. ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) , 2016, BMC Cancer.
[16] Gengxi Jiang,et al. Poultry and fish intake and risk of esophageal cancer: A meta‐analysis of observational studies , 2016, Asia-Pacific journal of clinical oncology.
[17] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[18] A. Mehrabi,et al. Brain metastasis from gastrointestinal cancers: a systematic review , 2014, International journal of clinical practice.
[19] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[20] E W Steyerberg,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.
[21] R. Chappell. Competing Risk Analyses: How Are They Different and Why Should You Care? , 2012, Clinical Cancer Research.
[22] Y. Bang,et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.
[23] Laura H. Tang,et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma , 2011, British Journal of Cancer.
[24] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Yoon-Koo Kang,et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.
[26] P. Rosenberg,et al. Age-specific trends in incidence of noncardia gastric cancer in US adults. , 2010, JAMA.
[27] M. Stuschke,et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] J. Fraumeni,et al. A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. , 2008, European journal of cancer.
[29] Yasuo Ohashi,et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.
[30] A. Chak,et al. Gastroesophageal reflux symptoms in patients with adenocarcinoma of the esophagus or cardia , 2006, Cancer.
[31] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[32] V. Gebski,et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. , 2005, The Lancet. Oncology.
[33] S. Lo,et al. Incidence and Factors Associated with Recurrence Patterns after Intended Curative Surgery for Gastric Cancer , 2003, World Journal of Surgery.
[34] S. Noh,et al. Recurrence following curative resection for gastric carcinoma , 2000, The British journal of surgery.
[35] M. Brennan,et al. Proximal gastric cancers resected via a transabdominal-only approach. Results and comparisons to distal adenocarcinoma of the stomach. , 1997, Annals of surgery.
[36] P. Laurén,et al. THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION. , 1965, Acta pathologica et microbiologica Scandinavica.
[37] Kevin K. Chang,et al. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma , 2018, Annals of surgery.
[38] T. Vaughan,et al. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. , 2013, Seminars in radiation oncology.
[39] M. Fujii,et al. Clinicopathological study of brain metastasis in gastric cancer patients , 2010, Surgery Today.
[40] J. Peters,et al. Etiology of intestinal metaplasia at the gastroesophageal junction , 2002, Surgical Endoscopy And Other Interventional Techniques.